Bristol Aims To Be First To Market With Novel Diabetes Drug Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol and AstraZeneca ink deal potentially worth over $1 billion to develop Bristol’s prospective first-in-class SGLT-2 inhibitor and DPP-4 candidate saxagliptin.